References
- O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-58 https://doi.org/10.1164/ajrccm.163.5.2007122
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44 https://doi.org/10.1038/31159
- Telenti A. Genetics of drug resistance in tuberculosis. In: Iseman MD, Huitt GA, eds. Clinics in chest medicine. Philadelphia: WB Saunders, 1997: 55-64]
- Lew WJ, Park YK, Kim HJ, Chang CH, Bai GH, Kim SK. The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations. Tuberc Respir Dis 2005; 59(3): 257-265 https://doi.org/10.4046/trd.2005.59.3.257
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62 https://doi.org/10.1164/rccm.167.4.603
- Joia SM, Michael LR, Adrienne RS, J Keith J, Felix AV, Sonya SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-81 https://doi.org/10.1016/S0140-6736(04)15496-2
- Tuberculosis Research Centre. Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38
- Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol 1996; 147: 52-9 https://doi.org/10.1016/0923-2508(96)80204-X
- Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-5 https://doi.org/10.1164/rccm.200305-682OC
- T.R. Sterling. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 2004; 8(12): 1396-1400
- Shim TS, Seoul Asan Medical Center (personal communication)
- Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small- molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-66 https://doi.org/10.1038/35016103
- Chapter 13. Vaccination to prevent tuberculosis and immunomodulatory therapy for persons with active disease. In: Iseman MD. A Clinician's guide to tuberculosis. Lippincott Williams & Wilkins, 2000: 417-25
- Han SK. The up-to-date of tuberculosis treatment. The annual course for respiratology 2002, Hanyang Medical School
- Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous Interferon- gamma in the treatment of refractory multidrug- resistant pulmonary tuberculosis. Tuberc Respir Dis 2004; 57: 226-33 https://doi.org/10.4046/trd.2004.57.3.226
- Park SK, Jun DS, Lee Y H, Lee DH. Treatment of multidrug-resistant pulmonary tuberculosis with Interferon- gamma subcutaneous injection. Tuberc Respir Dis 2003; 55 (suppl, 2): 84
- Koh WJ, Ahn CH, Kim CH, Ahn YM, Lim SY, Seo JY. The therapeutic effect of 6-month inhaled Interferon- gamma treatment in intractible multi-drug resisdtant pulmonary tuberculosis. Tuberc Respir Dis 2001; 51 (suppl, 2): 116
-
Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-
$\alpha$ in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156-62 https://doi.org/10.1164/ajrccm.158.4.9803065 - Onyebujoh PC, Levin JB, Fourie PB, et al. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354: 116-9 https://doi.org/10.1016/S0140-6736(98)10448-8
-
Jane MT, Utaiwan U, Anthomy M, Pasakorn A, Margaret B, Sanit M, et al. Thalidomide treatment reduces TNF-
$\alpha$ production and enhances weight gain in patients with pulmonary tuberculosis. Molecular Medicine 1995; 1(4): 384-97 https://doi.org/10.1007/BF01556866 - Wallis RS, Nsubuga P, Whalen C, Mugerwa RD. Pentoxifylline therapy in HIV-seropositive persons with tuberculosis: a randomized, controlled trial. J Inf Dis 1996; 174: 727-33 https://doi.org/10.1093/infdis/174.4.727
- Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005: 1-5
- Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci 2000; 97: 13853-8
- Hans L Rieder. Interventions for tuberculosis control and elimination. IUATLD 2002, 153-69
- Michael H Cynamon. Chemotherapeutic agents for Mycobacterial infections. In: Lloyd N Friedman, ed. Tuberculosis: current concepts and treatment, 2nd edition. CRC Press, 2001: 301-32